Cost consequences of HIV-associated lipoatrophy

References

• Ammassari , A. , Antinori , A. , Cozzi-Lepri , A. , Trotta , M.P. , Nasti , G. Ridolfo , A.L. 2002 . Relationship between HAART adherence and adipose tissue alterations . Journal of Acquired Immune Deficiency Syndromes , 31 ( Suppl. 3 ) : S140 – S144 .
   PubMed Web of Science ®Google Scholar
• Borelli , C. , Kunte , C. , Weisenseel , P. , Thoma-Greber , E. , Korting , H.C. and Konz , B. 2005 . Deep subcutaneous application of poly-L-lactic acid as a filler for facial lipoatrophy in HIV-infected patients . Skin Pharmacology and Physiology , 18 ( 6 ) : 273 – 278 .
   PubMed Web of Science ®Google Scholar
• Boston Clinic (UK) Ltd . 2007 . Retrieved October 5, 2007, from http://www.boston-clinic.co.uk/bc/public_html/pricelist/pricelist.html
   Google Scholar
• Burgess , C.M. and Quiroga , R.M. 2005 . Assessment of the safety and efficacy of poly-L-lactic acid for the treatment of HIV-associated facial lipoatrophy . Journal of the American Academy of Dermatology , 52 ( 2 ) : 233 – 239 .
   PubMed Web of Science ®Google Scholar
• Cameron , D. , da Silva , B. , Arribas , J. , Pulido , F. , Katner , H. , Wikstrom , K. , et al. . 2007 . Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r + ZDV/3TC induction followed by LPV/r monotherapy compared with EFV + ZDV/3TC . Paper presented at the 14th Conference on Retroviruses and Opportunistic Infections. Retrieved September 10, 2008, from http://www.retroconference.org/2007/Abstracts/30523.htm
   Google Scholar
• Cattelan , A.M. , Bauer , U. , Trevenzoli , M. , Sasset , L. , Campostrini , S. Facchin , C. 2006 . Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy . Archives of Dermatology , 142 ( 3 ) : 329 – 334 .
   PubMed Web of Science ®Google Scholar
• Collins , E. , Wagner , C. and Walmsley , S. 2000 . Psychosocial impact of the lipodystrophy syndrome in HIV infection . AIDS Reader , 10 ( 9 ) : 546 – 550 .
   PubMedGoogle Scholar
• Denton , A.B. and Tsaparas , Y. 2007 . Injectable hyaluronic acid for the correction of HIV-associated facial lipoatrophy . Archives of Otolaryngology—Head & Neck Surgery , 136 ( 4 ) : 563 – 567 .
   Google Scholar
• Echavez , M. and Horstman , W. 2005 . Relationship between lipoatrophy and quality of life . AIDS Reader , 15 ( 7 ) : 369 – 375 .
   PubMedGoogle Scholar
• Engelhard , P. 2006 . Correction options to lipoatrophy in HIV-infected patients . AIDS Patient Care and STDS , 20 ( 3 ) : 151 – 160 .
   PubMed Web of Science ®Google Scholar
• Funk , E. , Bressler , F.J. and Brissett , A.E. 2006 . Contemporary surgical management of HIV-associated facial lipoatrophy . Archives of Otolaryngology—Head & Neck Surgery , 134 ( 6 ) : 1015 – 1022 .
   Google Scholar
• Global Drugs Direct . 2007 . Retrieved October 5, 2007, from http://www.globaldrugsdirect.com/
   Google Scholar
• Hanke , C.W. and Redbord , K.P. 2007 . Safety and efficacy of poly-L-lactic acid in HIV lipoatrophy and lipoatrophy of aging . Journal of Drugs in Dermatology , 6 ( 2 ) : 123 – 128 .
   PubMedGoogle Scholar
• Hansen , A.B. , Lindegaard , B. , Obel , N. , Andersen , O. , Nielsen , H. and Gerstoft , J. 2006 . Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population . HIV Medicine , 7 ( 1 ) : 38 – 45 .
   PubMed Web of Science ®Google Scholar
• Haubrich , R. , Riddler , S. , DiRienzo , G. , Komarow , L. , Powderly , W. , Garren , K. , et al. . 2007 . Metabolic outcomes of ACTG 5142: A prospective, randomized, Phase III Trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection . Paper presented at the 14th Conference on Retroviruses and Opportunistic Infections. Retreived on September 10, 2008 from http://www.retroconference.org/2007/Abstracts/29065.htm
   Google Scholar
• Hornberger , J. , Holodniy , M. , Robertus , K. , Winnike , M. , Gibson , E. and Verhulst , E. 2007 . A systematic review of cost-utility analyses in HIV/AIDS: Implications for public policy . Medical Decision Making , 27 ( 6 ) : 789 – 821 .
   PubMed Web of Science ®Google Scholar
• Jacobson , D.L. , Knox , T. , Spiegelman , D. , Skinner , S. , Gorbach , S. and Wanke , C. 2005 . Prevalence of, evolution of, and risk factors for fat atrophy and fat deposition in a cohort of HIV-infected men and women . Clinical Infectious Diseases , 40 ( 12 ) : 1837 – 1845 .
   PubMed Web of Science ®Google Scholar
• Jones , D . 2005 HIV facial lipoatrophy: Causes and treatment options . Dermatologic Surgery , 31 (11 Pt 2) 1519 – 1529 ; discussion 1529 .
   PubMed Web of Science ®Google Scholar
• Jones , D.H. , Carruthers , A. , Orentreich , D. , Brody , H.J. , Lai , M.Y. Azen , S. 2004 . Highly purified 1000-cSt silicone oil for treatment of human immunodeficiency virus-associated facial lipoatrophy: An open pilot trial . Dermatologic Surgery , 30 ( 10 ) : 1279 – 1286 .
   PubMed Web of Science ®Google Scholar
• Lafaurie , M. , Dolivo , M. , Porcher , R. , Rudant , J. , Madelaine , I. and Molina , J.M. 2005 . Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patients . Journal of Acquired Immune Deficiency Syndromes , 38 ( 4 ) : 393 – 398 .
   PubMed Web of Science ®Google Scholar
• Loutfy , M.R. , Raboud , J.M. , Antoniou , T. , Kovacs , C. , Shen , S. Halpenny , R. 2007 . Immediate versus delayed polyalkylimide gel injections to correct facial lipoatrophy in HIV-positive patients . AIDS , 21 ( 9 ) : 1147 – 1155 .
   PubMed Web of Science ®Google Scholar
• Martin , A. , Smith , D.E. , Carr , A. , Ringland , C. , Amin , J. Emery , S. 2004 . Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: The MITOX extension study . AIDS , 18 ( 7 ) : 1029 – 1036 .
   PubMed Web of Science ®Google Scholar
• Martinez , E. , Garcia-Viejo , M.A. , Blanch , L. and Gatell , J.M. 2001 . Lipodystrophy syndrome in patients with HIV infection: Quality of life issues . Drug Safety , 24 ( 3 ) : 157 – 166 .
   PubMed Web of Science ®Google Scholar
• McComsey , G.A. , Ward , D.J. , Hessenthaler , S.M. , Sension , M.G. , Shalit , P. Lonergan , J.T. 2004 . Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: The results of the TARHEEL study . Clinical Infectious Diseases , 38 ( 2 ) : 263 – 270 .
   PubMed Web of Science ®Google Scholar
• Mest , D.R. and Humble , G. 2006 . Safety and efficacy of poly-L-lactic acid injections in persons with HIV-associated lipoatrophy: The US experience . Dermatologic Surgery , 32 ( 11 ) : 1336 – 1345 .
   PubMed Web of Science ®Google Scholar
• Milinkovic , A. , Lopez , S. , Vidal , S. , Miro , O. , Fernandez , X. , Amaiz , J. , et al. . 2005 . A randomized open study comparing the effect of reducing Stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing Stavudine . Paper presented at the 12th conference on retroviruses and opportunistic infections. Retrieved on September 10, 2008, from http://www.retroconference.org/2005/cd/Abstracts/25144.htm
   Google Scholar
• Moyle , G.J. , Lysakova , L. , Brown , S. , Sibtain , N. , Healy , J. Priest , C. 2004 . A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection . HIV Medicine , 5 ( 2 ) : 82 – 87 .
   PubMed Web of Science ®Google Scholar
• Moyle , G.J. , Sabin , C.A. , Cartledge , J. , Johnson , M. , Wilkins , E. Churchill , D. 2006 . A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy . AIDS , 20 ( 16 ) : 2043 – 2050 .
   PubMed Web of Science ®Google Scholar
• PharmacyChecker.com . 2007 . Retrieved October 5, 2007, from http://www.pharmacychecker.com/
   Google Scholar
• Physician Fee Schedule . 2007 . Retrieved October 5, 2007, from http://www.cms.hhs.gov/PhysicianFeeSched/
   Google Scholar
• Power , R. , Tate , H.L. , McGill , S.M. and Taylor , C. 2003 . A qualitative study of the psychosocial implications of lipodystrophy syndrome on HIV positive individuals . Sexually Transmitted Infections , 79 ( 2 ) : 137 – 141 .
   PubMed Web of Science ®Google Scholar
• Pujari , S.N. , Dravid , A. , Naik , E. , Bhagat , S. , Tash , K. Nadler , J.P. 2005 . Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India . Journal of Acquired Immune Deficiency Syndromes , 39 ( 2 ) : 199 – 202 .
   PubMed Web of Science ®Google Scholar
• Rajagopalan , R. , Laitinen , D. , & Birgitta , D. 2008 . Impact of lipoatrophy on quality of life in HIV patients receiving antiretroviral therapy (ART) . AIDS Care , 20 ( 10 ), 1197 – 1201 .
   PubMed Web of Science ®Google Scholar
• Ramon , Y. , Fodor , L. and Ullmann , Y. 2007 . Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy . Dermatology , 214 ( 2 ) : 151 – 154 .
   PubMed Web of Science ®Google Scholar
• Reynolds , N.R. , Neidig , J.L. , Wu , A.W. , Gifford , A.L. and Holmes , W.C. 2006 . Balancing disfigurement and fear of disease progression: Patient perceptions of HIV body fat redistribution . AIDS Care , 18 ( 7 ) : 663 – 673 .
   PubMed Web of Science ®Google Scholar
• Saghayam , S. , Chaguturu , S.K. , Kumarasamy , N. , Solomon , S. , Mayer , K.H. and Wanke , C. 2004 . Lipoatrophy is the predominant presentation of HIV-associated lipodystrophy in southern India . Clinical Infectious Diseases , 38 ( 11 ) : 1646 – 1647 .
   PubMed Web of Science ®Google Scholar
• Silvers , S.L. , Eviatar , J.A. , Echavez , M.I. and Pappas , A.L. 2006 . Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: One-year durability . Plastic and Reconstructive Surgery , 118 ( Suppl. 3 ) : 34S – 45 .
   PubMed Web of Science ®Google Scholar
• Sutinen , J. 2005 . Interventions for managing antiretroviral therapy-associated lipoatrophy . Current Opinion Infectious Diseases , 18 ( 1 ) : 25 – 33 .
   PubMed Web of Science ®Google Scholar
• The Lipoatrophy Resource center . 2007 . Retrieved October 5, 2007, from http://thebody.com/lipo/
   Google Scholar
• Treacy , P.J. and Goldberg , D.J. 2006 . Use of a biopolymer polyalkylimide filler for facial lipodystrophy in HIV-positive patients undergoing treatment with antiretroviral drugs . Dermatologic Surgery , 32 ( 6 ) : 804 – 808 .
   PubMed Web of Science ®Google Scholar
• Valantin , M.A. , Aubron-Olivier , C. , Ghosn , J. , Laglenne , E. , Pauchard , M. Schoen , H. 2003 . Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: Results of the open-label study VEGA . AIDS , 17 ( 17 ) : 2471 – 2477 .
   PubMed Web of Science ®Google Scholar
• van Griensven , J. , De Naeyer , L. , Mushi , T. , Ubarijoro , S. , Gashumba , D. Gazille , C. 2007 . High prevalence of lipoatrophy among patients on stavudine-containing first-line antiretroviral therapy regimens in Rwanda . Transactions of the Royal Society of Tropical Medicine and Hygiene , 101 ( 8 ) : 793 – 798 .
   PubMed Web of Science ®Google Scholar
• Werschler , P. , Rendon , M. , Sengelmann , R. , & Weinkle , S. 2006 . Recognition and treatment of facial lipoatrophy with volume restoration . Retrieved June 2008, from , http://doctor.medscape.com/viewprogram/5213_pnt
   Google Scholar
• WestCoastSkin 2007 Retrieved October 5, 2007, from http://www.westcoastskin.com/
   Google Scholar